Do analysts recommend NVCT or SCLX?

Nuvectis Pharma currently has a consensus price target of $39.00, indicating a potential upside of 43.44%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvectis Pharma is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NVCT or SCLX more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% Scilex -1,110.17% N/A -143.55%

Does the media favor NVCT or SCLX?

In the previous week, Nuvectis Pharma had 8 more articles in the media than Scilex. MarketBeat recorded 10 mentions for Nuvectis Pharma and 2 mentions for Scilex. Scilex's average media sentiment score of 0.93 beat Nuvectis Pharma's score of 0.88 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BCYC or SCLX?

Bicycle Therapeutics presently has a consensus target price of $14.00, indicating a potential upside of 241.46%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor BCYC or SCLX?

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 2 articles in the media. Bicycle Therapeutics' average media sentiment score of 0.93 equaled Scilex'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RNAC or SCLX?

Cartesian Therapeutics currently has a consensus price target of $32.60, indicating a potential upside of 246.07%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RNAC or SCLX more profitable?

Scilex has a net margin of -1,110.17% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics -8,550.65% N/A -28.25% Scilex -1,110.17% N/A -143.55%

Do analysts prefer ELDN or SCLX?

Eledon Pharmaceuticals presently has a consensus target price of $9.67, indicating a potential upside of 155.73%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ELDN or SCLX?

In the previous week, Eledon Pharmaceuticals had 4 more articles in the media than Scilex. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 2 mentions for Scilex. Scilex's average media sentiment score of 0.93 beat Eledon Pharmaceuticals' score of 0.46 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NAGE or SCLX?

Niagen Bioscience currently has a consensus target price of $10.50, indicating a potential upside of 207.02%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, NAGE or SCLX?

Niagen Bioscience has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $129.42M 2.10 $17.38M $0.21 16.29 Scilex $30.25M 2.00 -$358.73M -$40.47 N/A

Scilex (SCLX) Competitors

$7.11 +0.02 (+0.28%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$7.18 +0.06 (+0.91%)

As of 06/26/2026 07:52 PM Eastern

Compare

SCLX vs. NVCT, BCYC, RNAC, ELDN, and NAGE

Should you buy Scilex stock or one of its competitors? MarketBeat compares Scilex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scilex include Nuvectis Pharma (NVCT), Bicycle Therapeutics (BCYC), Cartesian Therapeutics (RNAC), Eledon Pharmaceuticals (ELDN), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry.

How does Scilex compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Nuvectis Pharma currently has a consensus price target of $39.00, indicating a potential upside of 43.44%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvectis Pharma is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvectis Pharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Scilex has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

In the previous week, Nuvectis Pharma had 8 more articles in the media than Scilex. MarketBeat recorded 10 mentions for Nuvectis Pharma and 2 mentions for Scilex. Scilex's average media sentiment score of 0.93 beat Nuvectis Pharma's score of 0.88 indicating that Scilex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Scilex	-1,110.17%	N/A	-143.55%

Nuvectis Pharma has higher earnings, but lower revenue than Scilex. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Scilex	$30.25M	2.00	-$358.73M	-$40.47	N/A

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 4.5% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Nuvectis Pharma beats Scilex on 10 of the 15 factors compared between the two stocks.

How does Scilex compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Bicycle Therapeutics has higher revenue and earnings than Scilex. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.93	-$218.96M	-$3.15	N/A
Scilex	$30.25M	2.00	-$358.73M	-$40.47	N/A

Bicycle Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Scilex has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 2 articles in the media. Bicycle Therapeutics' average media sentiment score of 0.93 equaled Scilex'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicycle Therapeutics has a net margin of -344.95% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Scilex	-1,110.17%	N/A	-143.55%

Bicycle Therapeutics presently has a consensus target price of $14.00, indicating a potential upside of 241.46%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bicycle Therapeutics beats Scilex on 11 of the 14 factors compared between the two stocks.

How does Scilex compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Cartesian Therapeutics has higher earnings, but lower revenue than Scilex. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	98.84	-$130.30M	-$5.90	N/A
Scilex	$30.25M	2.00	-$358.73M	-$40.47	N/A

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 4.5% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cartesian Therapeutics currently has a consensus price target of $32.60, indicating a potential upside of 246.07%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cartesian Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Scilex has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

In the previous week, Scilex had 1 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 2 mentions for Scilex and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.87 beat Scilex's score of 0.93 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cartesian Therapeutics	Very Positive
Scilex	Positive

Scilex has a net margin of -1,110.17% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Scilex	-1,110.17%	N/A	-143.55%

Summary

Cartesian Therapeutics beats Scilex on 10 of the 15 factors compared between the two stocks.

How does Scilex compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Eledon Pharmaceuticals had 4 more articles in the media than Scilex. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 2 mentions for Scilex. Scilex's average media sentiment score of 0.93 beat Eledon Pharmaceuticals' score of 0.46 indicating that Scilex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Scilex	-1,110.17%	N/A	-143.55%

Eledon Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Scilex has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Eledon Pharmaceuticals has higher earnings, but lower revenue than Scilex. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Scilex	$30.25M	2.00	-$358.73M	-$40.47	N/A

Eledon Pharmaceuticals presently has a consensus target price of $9.67, indicating a potential upside of 155.73%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Eledon Pharmaceuticals beats Scilex on 9 of the 15 factors compared between the two stocks.

How does Scilex compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Niagen Bioscience has a net margin of 14.29% compared to Scilex's net margin of -1,110.17%. Niagen Bioscience's return on equity of 22.68% beat Scilex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Scilex	-1,110.17%	N/A	-143.55%

Niagen Bioscience has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.10	$17.38M	$0.21	16.29
Scilex	$30.25M	2.00	-$358.73M	-$40.47	N/A

Niagen Bioscience has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Scilex has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Niagen Bioscience currently has a consensus target price of $10.50, indicating a potential upside of 207.02%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Scilex had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 2 mentions for Scilex and 1 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 equaled Scilex'saverage media sentiment score.

Company	Overall Sentiment
Niagen Bioscience	Positive
Scilex	Positive

Summary

Niagen Bioscience beats Scilex on 13 of the 15 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLX vs. The Competition

Export

Metric	Scilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$60.20M	$3.55B	$6.71B	$12.23B
Dividend Yield	N/A	2.25%	2.67%	6.12%
P/E Ratio	-0.18	21.56	26.03	24.18
Price / Sales	2.00	336.78	556.14	101.01
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	-0.29	8.34	10.77	6.35
Net Income	-$358.73M	$23.91M	$3.57B	$337.63M
7 Day Performance	-4.82%	6.85%	3.17%	0.43%
1 Month Performance	4.41%	4.25%	1.86%	0.14%
1 Year Performance	17.52%	65.92%	34.39%	27.64%

Scilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLX Scilex	0.9857 of 5 stars	$7.11 +0.3%	N/A	+34.2%	$60.20M	$30.25M	N/A	80
NVCT Nuvectis Pharma	2.359 of 5 stars	$11.15 +4.1%	$13.00 +16.6%	+252.7%	$284.09M	N/A	N/A	8
BCYC Bicycle Therapeutics	3.5457 of 5 stars	$4.15 +2.5%	$14.00 +237.3%	-43.7%	$282.73M	$72.86M	N/A	240	High Trading Volume
RNAC Cartesian Therapeutics	4.2526 of 5 stars	$8.60 -9.6%	$32.60 +279.1%	-17.8%	$279.42M	$2.80M	N/A	64	Positive News
ELDN Eledon Pharmaceuticals	1.8576 of 5 stars	$3.43 -3.9%	$9.67 +181.8%	+37.5%	$275.56M	N/A	N/A	10	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCLX) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scilex (SCLX) Competitors

SCLX vs. NVCT, BCYC, RNAC, ELDN, and NAGE

How does Scilex compare to Nuvectis Pharma?

Summary

How does Scilex compare to Bicycle Therapeutics?

Summary

How does Scilex compare to Cartesian Therapeutics?

Summary

How does Scilex compare to Eledon Pharmaceuticals?

Summary

How does Scilex compare to Niagen Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scilex (SCLX) Competitors

SCLX vs. NVCT, BCYC, RNAC, ELDN, and NAGE

How does Scilex compare to Nuvectis Pharma?

Do analysts recommend NVCT or SCLX?

Which has more risk & volatility, NVCT or SCLX?

Does the media favor NVCT or SCLX?

Is NVCT or SCLX more profitable?

Which has stronger earnings & valuation, NVCT or SCLX?

Do insiders and institutionals believe in NVCT or SCLX?

Summary

How does Scilex compare to Bicycle Therapeutics?

Which has better valuation & earnings, BCYC or SCLX?

Which has more risk and volatility, BCYC or SCLX?

Does the media favor BCYC or SCLX?

Is BCYC or SCLX more profitable?

Do analysts recommend BCYC or SCLX?

Do institutionals & insiders believe in BCYC or SCLX?

Summary

How does Scilex compare to Cartesian Therapeutics?

Which has higher earnings and valuation, RNAC or SCLX?

Do institutionals and insiders believe in RNAC or SCLX?

Do analysts prefer RNAC or SCLX?

Which has more volatility and risk, RNAC or SCLX?

Does the media refer more to RNAC or SCLX?

Is RNAC or SCLX more profitable?

Summary

How does Scilex compare to Eledon Pharmaceuticals?

Do insiders and institutionals believe in ELDN or SCLX?

Does the media refer more to ELDN or SCLX?

Is ELDN or SCLX more profitable?

Which has more risk & volatility, ELDN or SCLX?

Which has stronger earnings & valuation, ELDN or SCLX?

Do analysts prefer ELDN or SCLX?

Summary

How does Scilex compare to Niagen Bioscience?

Is NAGE or SCLX more profitable?

Which has better valuation & earnings, NAGE or SCLX?

Which has more risk and volatility, NAGE or SCLX?

Do insiders & institutionals believe in NAGE or SCLX?

Do analysts prefer NAGE or SCLX?

Does the media refer more to NAGE or SCLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools